ROBO1 _ DUTT1 (Internal)
- Known as:
- ROBO1 _ DUTT1 (Internal)
- Catalog number:
- Y213553
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- ROBO1 _ DUTT1 (Internal)
Related genes to: ROBO1 _ DUTT1 (Internal)
- Gene:
- ROBO1 NIH gene
- Name:
- roundabout guidance receptor 1
- Previous symbol:
- -
- Synonyms:
- DUTT1, FLJ21882, SAX3
- Chromosome:
- 3p12.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-26
- Date modifiied:
- 2016-04-25
Related products to: ROBO1 _ DUTT1 (Internal)
(I) LightCycler 1. 0; (Internal Control can't be used for this system) ; (II) LightCycler2. 0; (III) PE5700, MJ_Opticon etc. single color systems; (IV) ABI7000, ABI7300, ABI7500, ABI7900, ABI StepO1.0ml Self-Standing Cryovial Internal Thread w/ O-Ring Seal1.2ml Cryogenic Vial,Self-Standing, Internal Thread1.2ml Self-Standing Cryovial Internal Thread w per O-Ring Seal1.2ml Self-Standing Cryovial Internal Thread w per Silicone Wa1.2ml Self-Standing Cryovial Internal Thread w per Washer Seal1.2ml Self-Standing Cryovial Internal Thread w/ O-Ring Seal1.2ml Self-Standing Cryovial Internal Thread w/ O-Ring Seal1.2ml Self-Standing Cryovial Internal Thread w/ Silicone Wa1.2ml Self-Standing Cryovial Internal Thread w/ Silicone Wa1.2ml Self-Standing Cryovial Internal Thread w/Washer Seal1.2ml Self-Standing Cryovial Internal Thread w/Washer Seal1.2ml Self-Standing Cryovial Internal Thread w_ O-Ring Seal1.2ml Self-Standing Cryovial Internal Thread w_ Silicone Wa1.5-times expansion model of ear dissection, external, middle & internal ear, 4 parts Related articles to: ROBO1 _ DUTT1 (Internal)
- Enhancing NAD+ levels with nicotinamide riboside (NR) confers anti-inflammatory effects in human disease, although immunoregulatory mechanisms remain poorly characterized. We previously showed that ex vivo NR supplementation of primary CD4+ T cells from psoriatic individuals dampened immune responsiveness. To validate this in vivo, we performed a randomized, placebo-controlled NR supplementation study in individuals with mild-to-moderate psoriasis. Participants received oral NR (500 mg twice daily) or matching placebo for 4 weeks, with blood samples collected at baseline and after supplementation. NR reduced Th17 immune responsiveness. Bulk CD4+ T cell RNA-seq identified induction of the SLIT-ROBO signaling pathway. NR supplementation increased circulating SLIT2 levels and enhanced SLIT2 production in dermal fibroblasts. Pharmacologic and genetic interrogation in CD4+ T cells and fibroblasts demonstrated that SLIT2, acting through the ROBO1 receptor, inhibited Rho GTPase signaling, thereby attenuating canonical Th17 polarization and fibroblast inflammatory activation. These findings indicate that NAD+ augmentation exerts anti-inflammatory effects in psoriasis through SLIT2-ROBO1-mediated crosstalk between dermal fibroblasts and circulating CD4+ T cells, leading to suppression of Th17-driven inflammation. - Source: PubMed
Publication date: 2026/04/28
Han KimKlein Rachael JRecupero Thomas CRusso Anna ChiaraSharma RahulGupta Anand KHassanzadeh ShahinHuffstutler Rebecca DDagur Pradeep KFisk BryanRedekar Neelam RSack Michael N - The SLIT2/ROBO1 signaling axis regulates cellular migration and angiogenesis but also contributes to tumor progression and immune evasion in glioblastoma. Targeting this pathway with small molecules or antibodies remains challenging due to the shallow and extended nature of the SLIT2/ROBO1 interface. Here, we report the first computational design and experimental validation of macrocyclic peptides that inhibit SLIT2/ROBO1 binding. Twenty peptides were generated through a structure-guided interface mapping approach (Des3PI 2.0) and ranked using a contact-based scoring function. The top candidates were synthesized and evaluated using time-resolved fluorescence resonance energy transfer (TR-FRET) and biolayer interferometry (BLI) assays. Among the SLIT2-targeting peptides, SP4 and SP3 showed the most pronounced inhibition in TR-FRET (62% and 46%, respectively), with dose-dependent IC₅₀ values of 41 ± 5.2 μM and 68 ± 7.5 μM by BLI, confirming direct binding to the SLIT2/ROBO1 interface. The lead peptide SP4 also demonstrated favorable in vitro pharmacokinetic properties, including strong stability in simulated intestinal fluid (t₁/₂ = 7.6 h), high plasma integrity (89% at 1 h), and moderate metabolic stability in rat liver microsomes (t₁/₂ = 4.7 h). Collectively, this work provides a foundation for developing next-generation SLIT2/ROBO1 modulators for cancer and neuroimmune disorders. - Source: PubMed
Publication date: 2026/04/09
Abdel-Rahman Somaya ADelaunay MaxenceHa-Duong TâpGabr Moustafa - Craniofacial microsomia (CFM) encompasses a phenotypic continuum of congenital anomalies ranging from isolated microtia to more complex manifestations within the oculo-auriculo-vertebral spectrum, including Goldenhar syndrome, reflecting abnormal development of first and second pharyngeal arch-derived structures. While several genetic susceptibility loci have been reported, population-based evidence in individuals of European ancestry remains limited. Using nationwide data from FinnGen in the Finnish founder population, we identified a genome-wide significant association at a conserved intergenic locus near ROBO1, extending previous findings to a European ancestry cohort. The lead variant, rs62256696, lies within a regulatory region active in human embryonic craniofacial tissues during early development and shows concordant association with previously reported ROBO1 signals from non-European populations. Genetic correlation analyses demonstrated strong shared genetic architecture between CFM and auditory developmental phenotypes, consistent with the defined phenotypic continuum. Together, these findings extend previous observations to a new population context and support a role for regulatory variation at the ROBO1 locus in early craniofacial morphogenesis and auditory system development underlying craniofacial and auditory malformations. - Source: PubMed
Kaprio LauraKiukkonen AnuJuuri EmmaRice David POllila Hanna MStrausz Satu - Current diagnosis and surveillance of bladder cancer relies on cystoscopy which is invasive and user dependent. The urine mRNA panel, uRNAp, measures expression of 3 genes for identification of bladder cancer. Here we report validation of uRNAp for patients undergoing initial work-up for suspected bladder cancer and surveillance for bladder cancer. - Source: PubMed
Publication date: 2026/04/09
Mach Kathleen EKornberg ZacharyShkolyar EugeneLong JinLee Timothy JLa VinhYoo IhnaRodriguez GabrielaThong Alan EPrado Kris BShah Jay BLeppert John TSkinner Eila CLiao Joseph C - Temporomandibular joint osteoarthritis (TMJOA), a prevalent subtype of temporomandibular disorders, is characterized by progressive cartilage degradation and subchondral bone destruction. Despite advancements in understanding TMJOA pathogenesis, the molecular mechanisms underlying its progression remain unclear. In this study, elevated Slit guidance ligand 2 (SLIT2) expression was observed in TMJ tissues of unilateral anterior crossbite-induced TMJOA mice and synovial fluid from patients with TMJOA, correlating with disease severity. Furthermore, SLIT2 overexpression in transgenic mice intensified TMJOA progression, whereas heterozygous deletion of roundabout guidance receptor 1/2 (ROBO1/2) alleviated cartilage and bone damage. Mechanistically, SLIT2 promoted ROBO1-LRP6 complex formation, facilitating LRP6 phosphorylation and β-catenin nuclear translocation. This cascade upregulated matrix-degrading enzymes while downregulating cartilage structural proteins, exacerbating cartilage destruction and subchondral bone loss. These findings suggest that the SLIT2/ROBO1/LRP6 axis may represent a potential therapeutic target for TMJOA and provide mechanistic insights into disease progression. - Source: PubMed
Publication date: 2026/04/08
Luo GuanChen BaoyiChen WenjunLin HuiyiGuo WeiqiZhang QingbinLi JiangWang LijingPathak Janak LalYang YuhuiZhang WeijunZhang XiaoyuZheng BeiningWang ZiyiWei ShitingHe JiaxinZhou Wei-JieLiu Chang